frontMIND: Results With Tafasitamab Improve PFS 25% Over R-CHOP for High-Risk DLBCL

For decades, the standard first-line therapy for patients with diffuse large B-cell lymphoma (DLBCL) has been R-CHOP—rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone. There’s just one problem: Up to 40% of patients relapse following treatment, as DLBCL moves forward aggressively.

Despite improvements in supportive care and risk stratification, frontline treatment for DLBCL has remained largely unchanged since the early 2000s. Now, results for the frontMIND trial (NCT04824092), presented Saturday at the American Society of Clinical Oncology (ASCO) and simultaneously published in The Lancet, may challenge the status quo.^1,2

In frontMIND, investigators added tafasitimab (Monjuvi; Incyte) and lenalidomide—already known to have synergy when used in combination—to the R-CHOP backbone for patients with untreated high-intermediate-risk or high-risk DLBCL or high-grade B-cell lymphoma (HGBL). Results showed a 25% improvement in progression-free survival (PFS) over R-CHOP alone.^1,2

In a preview press briefing before ASCO, lead study author Georg Lenz, MD, of University Hospital Münster, Münster, Germany, highlighted the unmet need. “Obviously, we need better treatments, especially for these high-risk patients,” he said. Although patients who received the combination with tafasitamab had more treatment-emergent adverse events (TEAEs), “in general, the side effects were manageable, so therefore, we believe that the combination of tafasitamab and lenalidomide with R-CHOP is a potential new standard for frontline therapy for patients with intermediate or high-risk [diffuse] B-cell lymphoma or high-grade B-cell lymphoma.”

Clinical Rationale and Study Design

Study coauthor John Burke, MD, a medical oncologist with Rocky Mountain Cancer Centers and associate chair, US Oncology Hematology Research Program, explained why adding tafasitamab and lenalidomide to R-CHOP makes sense, something explored in an earlier phase 1b trial, FirstMIND (NCT04134936).

“Tafasitimab is a monoclonal antibody that targets CD19, and CD19 is present on B lymphocytes, and so it's present on the cancer cells,” he said. “Lenalidomide has a number of mechanisms of action, including stimulation in the immune system, so it improves what's called antibody-dependent cellular cytotoxicity, and also improves the macrophages' ability to kill cancer cells—so that’s the synergy there. The CD19 and the lenalidomide appear to be synergistic together and working together to help kill the B lymphocytes, so that was the rationale for putting those 2 together.”

Later, the combination was approved for transplant-ineligible patients with relapsed or refractory DLBCL following the phase 2 L-MIND study (NCT02399085) as well as FirstMIND, with frontMIND designed to answer the definitive phase 3 question involving patients not previously treated.

frontMIND was a global, phase 3, randomized, double-blind, placebo-controlled trial conducted across 298 centers in North America, South America, Europe, and the Asia-Pacific region. The trial enrolled 899 patients aged 18 to 80 years with previously untreated, high-intermediate or high-risk DLBCL or high-grade B-cell lymphoma (HGBL)—defined by an International Prognostic Index (IPI) score of 3 to 5. Patients were randomized 1:1 to receive either standard R-CHOP or an experimental regimen of tafasitamab plus lenalidomide added to R-CHOP (tafa-len-R-CHOP) for 6 cycles of 21 days each.

Primary End Point Is Progression-Free Survival

The primary endpoint was investigator-assessed PFS, defined as time from randomization to disease progression or death from any cause. With a median follow-up of 35.2 months—and a data cutoff of October 20, 2025—tafa-len-R-CHOP met its primary end point with a significant improvement in PFS over R-CHOP alone (HR, 0.75; 95% CI, 0.59-0.96; P = .019), representing a 25% reduction in the risk of disease progression or death.

The 2-year PFS rate was 71.1% with tafa-len-R-CHOP vs 62.9% with R-CHOP—an absolute difference of 8.2 percentage points. At 3 years, those rates were 67.3% vs 60.7%, respectively. In a post hoc analysis restricted to patients with centrally confirmed lymphoma subtypes (n=773), the benefit was even more pronounced (HR, 0.68; 95% CI, 0.52-0.88) and there was a 10.5–percentage point difference in 2-year PFS (72.7% vs 62.2%).

The Lancet article noted that local diagnostic misclassification may have diluted the efficacy signal in the full analysis set. “It has been noted that the increasing complexity of lymphoma diagnosis necessitates a central, uniform pathology review to ensure that the study cohort accurately represents the specific lymphoma subtypes included in the study,” the authors wrote.²

Event-free survival, which is a composite of progression, new antilymphoma treatment, or death, was also significantly improved (HR, 0.79; P = .026), with 2-year rates of 65.0% vs 56.7%.²

Response Rates Spark Theories

Overall survival data remain immature at this primary analysis, with a final analysis planned at 5 years. The interim HR was 0.85 (95% CI, 0.63-1.14; P = .270), not statistically significant, though directionally favorable. Overall, fewer deaths were observed in the tafa-len-R-CHOP arm (82 patients, 18%) than in the R-CHOP arm (95 patients, 21%).

Complete response (CR) rates at end of treatment were essentially identical between arms—65.2% with tafa-len-R-CHOP vs 65.2% with R-CHOP—a finding that appears to not align with improved PFS. The investigators hypothesize that tafasitamab and lenalidomide may be driving deeper molecular responses that are not captured by PET imaging. “Exploratory analyses for minimal residual disease based on cell-free DNA (cfDNA) by next-generation sequencing at end of treatment are ongoing, and will be published separately when completed,” the authors wrote.²

Subgroup Analyses Show a Signal Across Molecular Subtypes

An interesting finding of frontMIND concerns cell-of-origin subgroups, historically a major source of heterogeneity in DLBCL trials. Tafa-len-R-CHOP showed a statistically significant PFS benefit in patients with the activated B-cell (ABC)–like molecular subtype (HR, 0.59; 95% CI, 0.36-0.95), a population that has historically had worse outcomes with R-CHOP.

A directionally consistent—though not statistically significant—benefit was also seen in the more common germinal center B-cell (GCB)–like subtype (HR, 0.69; 95% CI, 0.40-1.19). This is noteworthy, because the only other recent trial for first-line DLBCL, POLARIX (NCT03274492), which led to approval of polatuzumab vedotin (Polivy; Roche)–based R-CHP, showed less evidence of benefit in GCB-like patients.

TEAEs Are Real but “ Manageable”

The addition of tafasitamab and lenalidomide came with a higher burden of AEs. Grade 3 or higher TEAEs occurred in 87% of patients on tafa-len-R-CHOP vs 76% on R-CHOP. The most common severe events were hematologic: events of grade 3 or higher neutropenia (69% vs 58%), thrombocytopenia (27% vs 14%), and anemia (24% vs 16%). Serious TEAEs were reported in 50% vs 39% of patients, respectively.

Fatal TEAEs occurred in 6% of tafa-len-R-CHOP patients vs 4% of R-CHOP patients, a difference attributable in part to the study's conduct during the COVID-19 pandemic—7 COVID-19–related deaths occurred in the tafa-len-R-CHOP arm vs 2 in the control arm. Fatal events from sepsis were also slightly higher (2% vs 1%), likely reflecting the deeper B-cell and myeloid suppression associated with the combination. Despite these differences in treatment-related mortality, total deaths at the time of primary analysis were numerically lower in the tafa-len-R-CHOP group, reflecting the lymphoma benefit outweighing the treatment toxicity. Crucially, adding tafasitamab and lenalidomide did not compromise the delivery of the R-CHOP backbone, with median relative dose intensities remaining at or near 100% for all R-CHOP components across the 6 cycles.

In separate interviews with The American Journal of Managed Care^®, both Lenz and Burke described the AEs as manageable and that patients benefited from a treatment that can keep an aggressive disease at bay; Lenz in particular highlighted the effect of COVID-19 on the data. He also said that the field continues to learn more about managing AEs, and that the tradeoff of being able to live longer—especially for younger patients—is well worth it. “I think a lot of the toxicity problems probably will also go away,” he said.

Burke, who works in a large community practice, sees this regimen as being adaptable to the community setting and that no special caregiver requirements will be needed. “Tafasitamab does not add by itself more toxicity, and doctors in the community are very used to giving R-CHOP; they're very used to giving lenolidomide,” he said.

As for balancing longer survival with the possibility of more AEs, Burke said, “The best way to help patients is to make them live longer and to make them live better.”

References

1. Lenz G, Trněný M, Burke JM, et al. frontMIND: Phase 3 study of tafasitamab (Tafa) plus lenalidomide (Len) and R-CHOP for patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL). J Clin Oncol. 2026;44(suppl 17):Abstr LBA7000. doi:10.1200/JCO.2026.44.17_suppl.LBA7000
2. Lenz G, Trněný M, Burke JM, et al. Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial. Lancet. Published online May 30, 2026. doi:10.1016/ S0140-6736(26)00866-4